Direct comparisons of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer patients stratified by estrogen receptor and menopausal status

Breast Cancer Research and Treatment

Volumn 49, Issue 1, 1998, Pages 51-60

  Nomura, Yasuo ^a   Shirouzu, Mitsunori ^a   Takayama, Takahiro ^a  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

Adjuvant therapy; Breast cancer; Chemoendocrine therapy; Chemotherapy; Endocrine therapy; Estrogen receptors; Menopause; Randomized trial

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; MITOMYCIN C; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MASTECTOMY; MENOPAUSE; ORAL DRUG ADMINISTRATION; OVARIECTOMY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; MITOMYCIN; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 0031840898     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005901622642     Document Type: Article

References (20)

1. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy, 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 339: 1-15, 71-85, 1992
2. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital, London: Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet 341: 1293-1298, 1993
3. Nomura Y, Tashiro H, Hisamatsu K, Shinozuka K: A randomized trial of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer stratified by estrogen receptors. Cancer 61: 2168-2175, 1988
4. Nomura Y, Tashiro H, Shinozuka K: Changes of steroid hormone receptor content by chemotherapy and/or endocrine therapy in advanced breast cancer. Cancer 55: 546-551, 1985
5. The Lifetest procedure. SAS/STAT User's Guide, Version 6, Fourth Edition, Volume 2, SAS Institute Inc., Cary, NC:SAS Institute Inc., 1027-1069, 1989
6. Lippman M, Bolan G, Huff K: The effects of estrogens and antiestrogens on hormone responsive human breast cancer in long-term tissue culture. Cancer Res 36: 4594-4601, 1976
7. Katzenellenbogen BS, Kendra KL, Norman MJ, Berthois Y: Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res 47: 4355-4360, 1987
8. Osborne CK, Boldt DH, Estrada P: Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. Cancer Res 44: 1433-1439, 1984
9. Sherman BM, Chapler FK, Crickard K, Wycoff D: Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women. J Clin Invest 64: 398-404, 1979
10. Jordan VC, Fritz NF, Langan-Fahey S, Thompson M, Tormey DC: Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst 83: 1488-1491, 1991
11. Sunderland MC, Osborne CK: Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J Clin Oncol 9: 1283-1297, 1991
12. Bines J, Oleske DM, Cobleigh MA: Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14: 1718-1729, 1996
13. Brincker H, Mouridsen HT, Andersen KW: Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer. Breast Cancer Res Treat 3: 91-95, 1983
14. Nomura Y, Tashiro H, Hisamatsu K: Drug compliance of adjuvant chemo-, endocrine-, or chemoendocrine treatment for operable breast cancer patients. J Jpn Soc Cancer Therapy 27: 670-677, 1992 (in Japanese with English abstract)
15. Osborne CK, Kitten L, Arteaga CL: Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. J Clin Oncol 7: 710-717, 1989
16. Boccardo F, Rubagotti A, Amoroso D, Sismondi P, Genta F, Nenci I, Piffanelli A, Farris A, Castagnetta A, Traina A, Cappellini M, Pacini P, Sassi M, Malacarne P, Donati D, Mustacchi G, Galletto L, Schieppati G, Villa F, Bolognesi A, Gallo L: Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. Eur J Cancer 28: 673-680, 1992
17. Fisher B, Redmond C, Brown A, Fisher ER, Wolmark N, Bowman D, Plotkin D, Wolter J, Bornstein R, Legault-Poisson S, Saffer EA: Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project trial. J Clin Oncol 4: 459-471, 1986
18. Fisher B, Redmond C, Legault-Poisson S, Legault-Poisson S, Dimitrov NV, Brown AM, Wickerham DL, Wolmark N, Margolese RG, Bowman D, Glass AG, Kardinal CG, Robidoux A, Jochimsen P, Cronin W, Deutsch M, Fisher ER, Meyers DB, Hoehn JL: Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of node-positive breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 8: 1005-1018, 1990
19. Fisher B, Digham J, De Cillis A, Wickerham D, Wolmark N, Emir B, Dimitrov N, Abramson N, Atkins J, Shibata H, Deschenes L: The worth of chemotherapy and tamoxifen (TAM) over TAM alone in node negative patients with estrogen-receptor (ER) positive invasive breast cancer (BC): first results from NSABP B-20. Proc ASCO 16: 1 (abstract), 1997
20. Albain K, Green S, Osborne K, Cobau C, Levine E, Ingle J, Pritchard K, Schneider J, O'Sullivan J, Hess E, Martino S: Tamoxifen (T) versus cyclophosphamide, adriamycin and 5FU plus either concurrent or sequential T in postmenopausal, receptor (+), node (+) breast cancer: a Southwest Oncology Group phase III intergroup trial (SWOG-8814, INT-0100). Proc ASCO 16: 450 (abstract), 1997